


Supplementary Data




SUPPLEMENTARY FIG. S1. Mechanical properties of rings treated with TGF-β1. Sample groups included untreated rings with no microspheres, rings treated with 10 ng/mL exogenous TGF-β1, rings with unloaded gelatin microspheres untreated or treated with exogenous TGF-β1, and rings with TGF-β1-loaded microsphere incorporation, but no exogenous TGF-β1. Mean values for (A) UTS, (B) MTM, (C) failure load, and (D) failure strain were calculated from stress-strain curves for each sample. * $p < 0.05$. Values are mean \pm SD, sample size for each group shown on bars. TGF-β1, transforming growth factor beta 1; UTS, ultimate tensile stress; MTM, maximum tangent modulus; SD, standard deviation.

Supplementary Methods


Cell culture

For supplementary experiments, testing was repeated with human coronary artery cells from a different manufacturer

(Lonza). These cells were cultured in SmGM-2 complete medium (Lonza), containing 5% fetal bovine serum, 0.1% epidermal growth factor, 0.2% fibroblast growth factor-B, 0.1% insulin, 0.1% gentamicin sulfate, amphotericin-B, and was also supplemented with 1% penicillin–streptomycin (Mediatech).



SUPPLEMENTARY FIG. S2. Effects of TGF-β1 treatment in SMC rings sourced from a different donor. Rings were seeded in growth medium, switched to differentiation medium at day 1, and cultured for a total of 14 days. Rings were photographed (A–E) before and (F–J) after removal from the agarose posts to measure changes in ring inner diameter and wall thickness. (A, F) Untreated control ring with no microspheres. (B, G) Tissue rings treated with 10 ng/mL soluble exogenous (exo) TGF-β1 in the culture medium. Tissue rings with unloaded gelatin microspheres (0.6 mg/million cells) (C, H) untreated or (D, I) treated with 10 ng/mL exogenous TGF-β1. (E, J) Tissue rings with microspheres loaded with TGF-β1, but no exogenous TGF-β1 in the medium. Tissue rings contracted after they were removed from agarose posts, resulting in changes in (K) inner diameter and (L) thickness. Initial images and thicknesses were measured using the DVT imaging system (A–E), while secondary measurements were taken with the stereoscope (F–J). Scale = 1 mm. **p* < 0.05. Values are mean ± standard error of mean, sample size for each group shown on bars. SMC, smooth muscle cell.



SUPPLEMENTARY FIG. S3. Effects of TGF- β 1 treatment on SMC protein expression in rings self-assembled from human SMCs from a different donor. Rings were seeded in growth medium, switched to differentiation medium at day 1, and cultured for a total of 14 days. (**A, F**) Control (untreated) rings. (**B, G**) Rings cultured with exogenous TGF- β 1 (10 ng/mL) added to the medium. Rings with unloaded microspheres (0.6 mg per million cells) (**C, H**) untreated or (**D, I**) treated with 10 ng/mL exogenous TGF- β 1. (**E, J**) Rings with TGF- β 1-loaded microspheres (0.6 mg microspheres per million cells) but without exogenous TGF- β 1. Rings were stained for (**A–E**) smooth muscle alpha actin and (**F–J**) calponin (*green* fluorescence). Nuclei are shown in *blue* (Hoechst). Scale = 100 μ m.